ZNF217 and cancer: Altogether, besides assessing ZNF217/ZNF217 expression levels on tumor biopsies, assessing circulating lncRNAs/circRNAs/miRNAs targeting ZNF217 or circulating DNA methylation status at ZNF217 locus could represent a surrogate biomarker of poor prognosis or poor therapeutic response in cancer.